Identifying targets for topical RNAi therapeutics in psoriasis: Assessment of a new in vitro psoriasis model

Archives of Dermatological Research

Volumn 305, Issue 6, 2013, Pages 501-512

  Bracke, S ^a   Desmet, E ^a   Guerrero Aspizua, S ^b   Tjabringa, S G ^d   Schalkwijk, J ^d   Van Gele, M ^a   Carretero, M ^c   Lambert, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CIEMAT   (Spain)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

In vitro model; miRNA; Psoriasis; RNA interference; siRNA

Indexed keywords

BETA DEFENSIN 4; CYCLIC AMP; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MICRORNA; MICRORNA 146A; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CAMP GENE; CONTROLLED STUDY; DEFB4 GENE; DOWN REGULATION; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KERATINOCYTE; MICRORNA 203 GENE; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; UPREGULATION;

CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC THERAPY; HUMANS; INFLAMMATION MEDIATORS; KERATINOCYTES; MICRORNAS; PHENOTYPE; PSORIASIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84880916443     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1379-9     Document Type: Article

References (48)

1. Amigo M, Schalkwijk J, Olthuis D, De Rosa S, Paya M, Terencio MC, Lamme E (2006) Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation. Life Sci 79(25):2395-2404
2. Bando M, Hiroshima Y, Kataoka M, Shinohara Y, Herzberg MC, Ross KF, Nagata T, Kido J (2007) Interleukin-1alpha regulates antimicrobial peptide expression in human keratinocytes. Immunol Cell Biol 85(7):532-537
3. Banno T, Gazel A, Blumenberg M (2004) Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 279(31):32633-32642
4. Bernerd F, Magnaldo T, Darmon M (1992) Delayed onset of epidermal differentiation in psoriasis. J Invest Dermatol 98(6):902-910
5. Bigler J, Rand HA, Kerkof K, Timour M, Russell CB (2013) Cross-study homogeneity of psoriasis gene expression in skin across a large expression range. PLoS One 8(1):e52242
6. Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711-719
7. Capon F, Burden AD, Trembath RC, Barker JN (2012) Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol 132(3 Pt 2):915-922. doi: 10.1038/jid.2011.395
8. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG (2011) Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131(3):677-687
9. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A (2012) The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 51(4):389-395 quiz 395-388
10. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12(5):329-340. doi: 10.1038/nrg2968
11. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-811
12. Frohm Nilsson M, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M (1999) The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 67(5):2561-2566
13. Geusens B, Sanders N, Prow T, Van Gele M, Lambert J (2009) Cutaneous short-interfering RNA therapy. Expert Opin Drug Deliv 6(12):1333-1349. doi: 10.1517/17425240903304032
14. Geusens B, Strobbe T, Bracke S, Dynoodt P, Sanders N, Van Gele M, Lambert J (2011) Lipid-mediated gene delivery to the skin. Eur J Pharm Sci 43(4):199-211
15. Girolomoni G, Mrowietz U, Paul C (2012) Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167(4):717-724
16. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB (1989) Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 86(16):6367-6371
17. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, Voorhees JJ, Abecasis GR, Elder JT (2010) Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 130(7):1829-1840
18. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, Khatcherian A, Novitskaya I, Carucci JA, Bergman R, Krueger JG (2008) Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 181(10):7420-7427
19. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van de Kerkhof PC, Traupe H, de Jongh G, den Heijer M, Reis A, Armour JA, Schalkwijk J (2008) Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 40(1):23-25
20. Ichihara A, Jinnin M, Yamane K, Fujisawa A, Sakai K, Masuguchi S, Fukushima S, Maruo K, Ihn H (2011) microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br J Dermatol 165(5):1003-1010
21. Iizuka H, Takahashi H, Honma M, Ishida-Yamamoto A (2004) Unique keratinization process in psoriasis: late differentiation markers are abolished because of the premature cell death. J Dermatol 31(4):271-276
22. Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, Zhang W, Bowcock AM (2011) Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 20(20):4025-4040. doi: 10.1093/hmg/ddr331
23. Kupper TS, Fuhlbrigge RC (2004) Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4(3):211-222
24. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gilliet M (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449(7162):564-569
25. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN (1995) Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 133(4):501-511
26. Lerman G, Avivi C, Mardoukh C, Barzilai A, Tessone A, Gradus B, Pavlotsky F, Barshack I, Polak-Charcon S, Orenstein A, Hornstein E, Sidi Y, Avni D (2011) MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One 6(6):e20916
27. Mee JB, Johnson CM, Morar N, Burslem F, Groves RW (2007) The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 171(1):32-42
28. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. The New England journal of medicine 361(5):496-509. doi: 10.1056/NEJMra0804595
29. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, Khatcherian A, Gonzalez J, Pierson KC, White TR, Pensabene C, Coats I, Novitskaya I, Lowes MA, Krueger JG (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159(5):1092-1102
30. Oka A, Mabuchi T, Ozawa A, Inoko H (2012) Current understanding of human genetics and genetic analysis of psoriasis. J Dermatol 39(3):231-241. doi: 10.1111/j.1346-8138.2012.01504.x
31. Pol A, Bergers M, van Ruissen F, Pfundt R, Schalkwijk J (2002) A simple technique for high-throughput screening of drugs that modulate normal and psoriasis-like differentiation in cultured human keratinocytes. Skin Pharmacol Appl Skin Physiol 15(4):252-261
32. Pol A, van Ruissen F, Schalkwijk J (2002) Development of a keratinocyte-based screening model for antipsoriatic drugs using green fluorescent protein under the control of an endogenous promoter. J Biomol Screen 7(4):325-332
33. Reich K, Bewley A (2011) What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol 25 Suppl 4:15-20
34. Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A, Stahle M, Pivarcsi A (2007) MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2(7):e610
35. Suarez-Farinas M, Lowes MA, Zaba LC, Krueger JG (2010) Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One 5(4):e10247
36. Svensson L, Ropke MA, Norsgaard H (2012) Psoriasis drug discovery: methods for evaluation of potential drug candidates. Expert Opin Drug Discov 7(1):49-61
37. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103(33):12481-12486
38. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, Suarez-Farinas M (2012) Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One 7(9):e44274
39. Tjabringa G, Bergers M, van Rens D, de Boer R, Lamme E, Schalkwijk J (2008) Development and validation of human psoriatic skin equivalents. Am J Pathol 173(3):815-823
40. Van Ruissen F, de Jongh GJ, Zeeuwen PL, Van Erp PE, Madsen P, Schalkwijk J (1996) Induction of normal and psoriatic phenotypes in submerged keratinocyte cultures. J Cell Physiol 168(2):442-452
41. Vandesompele J, De Paepe A, Speleman F (2002) Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 303(1):95-98
42. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034
43. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal MalefytR (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950-957
44. Xu N, Brodin P, Wei T, Meisgen F, Eidsmo L, Nagy N, Kemeny L, Stahle M, Sonkoly E, Pivarcsi A (2011) MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 131(7):1521-1529
45. Yi R, Poy MN, Stoffel M, Fuchs E (2008) A skin microRNA promotes differentiation by repressing 'stemness'. Nature 452(7184):225-229
46. Zeeuwen PL, de Jongh GJ, Rodijk-Olthuis D, Kamsteeg M, Verhoosel RM, van Rossum MM, Hiemstra PS, Schalkwijk J (2008) Genetically programmed differences in epidermal host defense between psoriasis and atopic dermatitis patients. PLoS One 3(6):e2301
47. Zeng Y, Yi R, Cullen BR (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100(17):9779-9784
48. Zibert JR, Lovendorf MB, Litman T, Olsen J, Kaczkowski B, Skov L (2010) MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 58(3):177-185